Therapeutic Advances in Mycobacterium avium Complex Pulmonary Disease: Current Treatments and Emerging Host-Directed Approaches
International Journal of Molecular Sciences · 04.11.2026 · 27 (21) · 9872
DOI: 10.3390/ijms27219872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.11.2026. Verfasst von Nooneh Melody Khachatourian und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, USA. Hauptthemen laut MEDLINE: Mycobacterium avium Complex, Mycobacterium avium-intracellulare Infection, Lung Diseases, Anti-Bacterial Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Mycobacterium avium complex (MAC) is the leading cause of non-tuberculous mycobacterial (NTM) pulmonary disease, with increasing incidence among aging and immunocompromised populations. Despite guideline-recommended multidrug therapy consisting of a macrolide, ethambutol, and a rifamycin, treatment remains prolonged and complicated by incomplete culture conversion, adverse effects, recurrence, and antimicrobial resistance. Intracellular persistence, biofilm formation, and intrinsic resistance mechanisms further challenge disease management. This review summarizes MAC pathogenesis, host immune responses, current treatments, and emerging therapeutic strategies. Promising approaches include novel antimicrobial agents, optimized multidrug regimens, drug repurposing, inhaled delivery systems, and host-directed therapies. Particular emphasis is placed on glutathione (GSH), an intracellular antioxidant with immunomodulatory properties, as a potential adjunctive therapy. Experimental studies suggest that GSH and its precursor N-acetylcysteine may influence oxidative stress, inflammatory responses, and antimycobacterial activity. However, MAC-specific evidence remains primarily in vitro, and clinical efficacy in MAC pulmonary disease has not been established. Findings from related mycobacterial infections provide mechanistic insights but cannot be directly extrapolated to MAC pulmonary disease. Further preclinical and clinical studies are needed to determine whether GSH-based interventions can safely complement conventional antimicrobial therapy and improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, USA.
ORCID-Profile: Nooneh Melody Khachatourian, Vishwanath Venketaraman
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Khachatourian, N. M., Takhmazian, R., & Venketaraman, V. (2026). Therapeutic Advances in Mycobacterium avium Complex Pulmonary Disease: Current Treatments and Emerging Host-Directed Approaches. International Journal of Molecular Sciences, 27(21), 9872. https://doi.org/10.3390/ijms27219872
Vancouver
Khachatourian NM, Takhmazian R, Venketaraman V. Therapeutic Advances in Mycobacterium avium Complex Pulmonary Disease: Current Treatments and Emerging Host-Directed Approaches. International Journal of Molecular Sciences. 2026;27(21):9872. doi:10.3390/ijms27219872
BibTeX
@article{Khachatourian2026,
author = {Khachatourian, Nooneh Melody and Takhmazian, Rubina and Venketaraman, Vishwanath},
title = {Therapeutic Advances in Mycobacterium avium Complex Pulmonary Disease: Current Treatments and Emerging Host-Directed Approaches},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9872},
doi = {10.3390/ijms27219872}
}
EUVIMED